CONMED (NASDAQ: CNMD) and Second Sight Medical Products (NASDAQ:EYES) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.1%. Second Sight Medical Products does not pay a dividend. CONMED pays out 42.3% of its earnings in the form of a dividend.
This table compares CONMED and Second Sight Medical Products’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CONMED||$796.39 million||2.58||$55.48 million||$1.89||38.82|
|Second Sight Medical Products||$7.96 million||15.49||-$28.51 million||($0.59)||-3.14|
CONMED has higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.
This table compares CONMED and Second Sight Medical Products’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-387.35%||-307.76%||-194.77%|
Institutional & Insider Ownership
95.4% of CONMED shares are owned by institutional investors. Comparatively, 10.7% of Second Sight Medical Products shares are owned by institutional investors. 3.1% of CONMED shares are owned by company insiders. Comparatively, 48.3% of Second Sight Medical Products shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
CONMED has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Second Sight Medical Products has a beta of 3.15, indicating that its stock price is 215% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for CONMED and Second Sight Medical Products, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
CONMED presently has a consensus target price of $59.50, suggesting a potential downside of 18.90%. Second Sight Medical Products has a consensus target price of $5.00, suggesting a potential upside of 170.27%. Given Second Sight Medical Products’ stronger consensus rating and higher possible upside, analysts plainly believe Second Sight Medical Products is more favorable than CONMED.
CONMED beats Second Sight Medical Products on 9 of the 15 factors compared between the two stocks.
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company's products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.
About Second Sight Medical Products
Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.